Akoya Biosciences, Inc. reported its financial results for the first quarter of 2025, showing a decrease in revenue to $16.6 million, down 9.8% from $18.4 million in the same period the previous year. Despite this decline, the company improved its gross margin to 59.3%, up from 45.7%. The company's operating loss for the quarter was reported at $13.4 million, marking a 37.9% improvement compared to a loss of $21.6 million in the prior year period. Operating expenses also saw a reduction, totaling $23.3 million, down 22.3% from $30.0 million. In addition to financial results, Akoya highlighted a significant business development: the selection of its PhenoCycler-Fusion platform for a landmark study funded by Cancer Grand Challenges. This study aims to address cancer inequities through comprehensive spatial analysis and will contribute to the creation of a new Biobank and Data Repository. The company also noted an increase in its installed base, reaching 1,359 instruments by the end of the quarter, a 12.0% rise from the previous year. Publications citing Akoya's technology increased to 1,891, demonstrating a 44.7% year-over-year growth. Akoya is preparing for its impending acquisition by Quanterix Corporation and will not be hosting an earnings conference call or offering forward-looking guidance at this time.